Ibalizumab efficacy and safety through 48 weeks of treatment: results of an expanded access protocol (TMB-311) [abstract].
Déc. 20, 2019
20 Déc. 2019
Emu B, DeJesus E, Berhe M, et al.
Location
6 (suppl 2):S303. Proceedings of IDWeek, 2019.
Ordre du jour
Open Forum Infect Dis.